TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05983536

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV Ag +Ab Assay Kit (Sysmex)
Description: Using the HIV Ag +Ab Assay Kit (Sysmex) to detect the HIV antigen and antibody in serum, then verified by Human Immunodeficiency Virus (HIV 1+2) Antibody Test Kit (Immunoimprinting). The specificity of the HIV Ag +Ab Assay Kit (Sysmex) is calculated according to the specificity calculation formula.

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV Ag +Ab Assay Kit (Sysmex)
Description: Using the HIV Ag +Ab Assay Kit (Sysmex) to detect the HIV antigen and antibody in serum, then verified by Human Immunodeficiency Virus (HIV 1+2) Antibody Test Kit (Immunoimprinting). The specificity of the HIV Ag +Ab Assay Kit (Sysmex) is calculated according to the specificity calculation formula.
Study: NCT05232227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine double dose over 14 days
Description: Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine single dose over 14 days
Description: Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US
Study: NCT00546026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placental function assessment
Description: Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
Study: NCT04825561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-208
Description: PO, Once daily(QD), 24weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2081
Description: PO, Once daily(QD), 24weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of AD-208
Description: PO, Once daily(QD), 24weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of AD-208
Description: PO, Once daily(QD), 24weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of AD-2081
Description: PO, Once daily(QD), 24weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of AD-2081
Description: PO, Once daily(QD), 24weeks
Study: NCT05206097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci \& Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.
Study: NCT05892510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial tenecteplase injection at the completion of thrombectomy
Description: Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intra-arterial bolus of 0.9% Sodium Chloride solution
Study: NCT06082479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraoral cryotherapy,ice gel
Description: A cold pack (ice gel enveloped by a sealed plastic cover) measuring 2.5 x 5 centimetres was placed intraorally on the vestibular surface of the treated tooth. Each cold pack was kept for ten minutes.3 packs were used for each patient, for a total time of 30 minutes.Patients were instructed to remove the cold pack for 1-2 minutes if they felt extreme cold or a burning sensation .The temperature of the gel was checked by a digital thermometer (Brannan, UK) after it was removed from the freezer and kept in an ice box (Cosmoplast, UAE) containing a cooling gel (Exam Packaging, Belgium).
Study: NCT05620524

Intervention type: DRUG
Intervention: Extra blood samples for determining exposure to 5-FU
Description: Extra blood samples for determining exposure to 5-FU
Study: NCT04794257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromonitoring of the recurrent laryngeal nerves
Description: The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromonitoring of the recurrent laryngeal nerves
Description: The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
Study: NCT03962400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reinforcement Learning
Description: New computer based procedure for determining dose using a decision support tool

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heath Care Provider
Description: Warfarin dose will be determined by a qualified health care provider
Study: NCT05063994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Over-encapsulated hydrocortisone modified-release capsules for oral administration - 5mg and 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef
Description: Over-encapsulated immediate-release hydrocortisone capsules for oral administration - 5mg and 20mg
Study: NCT05348252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Journey App
Description: The group will receive all information and insctructions on discontinuing PPI use through the Patient Journey App which timely deliveres all information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information folder
Description: The group will receive all information and instructions on discontinuing PPI use through an information folder.
Study: NCT04895501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: running flexible shoes
Description: 21kms of running flexible shoes followed by a time-to-exhaustion run.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: running flexible shoes
Description: 21kms of running flexible shoes followed by a time-to-exhaustion run.
Study: NCT05728476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy combined with ILM peeling
Description: Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conbercept intravitreal injection
Description: Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
Study: NCT04716985

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MOLECULAR HYDROGEN
Description: Magnesium Tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO MAGNESIUM
Description: Magnesium carbonate tablet
Study: NCT05025930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic surgical instrument control system (SP1000: single-port laparoscopy)
Description: The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)
Description: The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
Study: NCT06157450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Participants receive ZSP1273 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Participants receive ZSP1273 orally.
Study: NCT06529055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Pouch - Nicotine
Description: Ingestion of a randomized oral nicotine pouch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Pouch - Nicotine
Description: Ingestion of a randomized oral nicotine pouch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Pouch - Caffeine
Description: Ingestion of a randomized oral caffeine pouch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Pouch - Caffeine
Description: Ingestion of a randomized oral caffeine pouch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Pouch - Placebo
Description: Ingestion of a randomized oral placebo pouch
Study: NCT05221359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExOlin®
Description: Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Use of NovoRapid insulin during all periods of the clinical investigations
Study: NCT05299697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 15 mg
Description: Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 22.5 mg
Description: Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
Study: NCT04892914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embr thermal device
Description: Participants use the Embr thermal device for 4 weeks
Study: NCT06049225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Tech
Description: Access to technological platform and weekly health coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Tech
Description: Weekly email with educational content and weekly health coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: No technology access or health coaching
Study: NCT06139497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative research
Description: A quantitative cross-sectional assessment of disability will be carried out.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative research
Description: A quantitative cross-sectional assessment of disability will be carried out.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative survey
Description: A qualitative survey will be conducted on the impact of functional limitations on participants' lives, on biographical reconstruction strategies and on PLWHIV's perception of the intervention and its implementation.
Study: NCT04709952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation_High real
Description: Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in high real stimulation group (2mA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation_Low real
Description: Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in Low real stimulation group (1mA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation_Sham
Description: Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in sham stimulation group (0mA).
Study: NCT05267431

Intervention type: DRUG
Intervention: Biological Drug
Description: Different biological drugs
Study: NCT05216575

Intervention type: DRUG
Intervention: Administration of Almitrine
Description: Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
Study: NCT04879368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: human IgG4 monoclonal antibody inhibitor of PD-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/Tipracil
Description: The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
Study: NCT05563558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Included in arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Included in arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Included in arm/group description
Study: NCT06519331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Research FibroScan (FS)
Description: Patients #1 to #25:~Exam 1: Examination with Research FibroScan. Exam 2: Examination with the Reference FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #26 to #75:~Exam 1: Examination with the Research or Reference FibroScan. Exam 2: Examination with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #76 to #114:~Exams 1 \& 2: 2 consecutive examinations with the Research or Reference FibroScan.~Exams 3 \& 4: 2 consecutive examinations with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exams 1 \& 2.
Study: NCT05327452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Home-Based Exercise
Description: Online supervised aerobic and resistance exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised Home-Based Exercise
Description: Unsupervised aerobic and resistance exercise (UNSUP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Stretching Program
Study: NCT05430906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 - Chemotherapy
Description: AK104 10mg/kg then \[paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)\] and \[carboplatin (AUC5 or 6) or cisplatin (75mg/m²)\] of each 21-day cycle
Study: NCT06130995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix and Enzalutamide
Description: Dose level of Relugolix and Enzalutamide Safety Lead-in Cohort, 3-12 patient. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; 120-160 mg, oral, once daily.~Dose Expansion Cohort, up to 34 patients. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; To be determined by safety lead-in cohort.~One cycle = 3 months The dose limiting toxicity (DLT) period is the first 28 days~Neoadjuvant ADT: 6 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Concurrent ADT during Radiation Therapy; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Maintenance ADT: Additional 18 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily
Study: NCT05111717

Intervention type: DRUG
Intervention: Desflurane
Description: Peripheral venous blood samplesof patients will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). Anesthesia maintenance will be provided with 40% O₂ and minimum alveolar concentration (MAC) in 60% air with 6% desflurane. DNA will be obtained from blood samples with the help of DNA isolation kit, and global DNA methylation analysis will performed by ELISA method.
Study: NCT05087589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5mg was taken orally twice a day for 6 months
Study: NCT05081388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14256
Description: Sub-cutaneous (SC) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14256
Description: Sub-cutaneous (SC) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imdevimab
Description: SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imdevimab
Description: SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imdevimab
Description: SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab + imdevimab
Description: SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC single dose